Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a ...

In just its fifth full quarter on the market, the world’s first treatment for metabolic dysfunction-associated steatohepatitis (MASH) is now annualizing at more than $1 billion.

In November 2025, Madrigal Pharmaceuticals announced positive two-year results from the open-label compensated MASH cirrhosis arm of its Phase 3 MAESTRO-NAFLD-1 trial, showing statistically ...

The average one-year price target for Madrigal Pharmaceuticals (NasdaqGS:MDGL) has been revised to $562.78 / share. This is ...

Fintel reports that on November 20, 2025, Oppenheimer maintained coverage of Madrigal Pharmaceuticals (NasdaqGS:MDGL) with a ...

At the Liver Meeting, there was positive news about Rezdiffra for MASH and Vir's Hep delta candidate, along with hope on ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Madrigal Pharmaceuticals, Inc. has secured a $500 million senior secured credit facility from Blue Owl Capital to advance its pipeline focused on treating metabolic dysfunction-associated ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth-quarter ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.